$COST

Are Wall Street Analysts Predicting Costco Wholesale Stock Will Climb or Sink?

Costco Wholesale (COST) has lagged the S&P 500 over 52 weeks, down 5.1% versus SPX up 19.9%, though it is up 9.1% YTD. The article cites concerns about slowing sales growth, fading gasoline-driven traffic, membership saturation, rising costs, and tariff uncertainty. For FY ending Aug 2026, analysts expect EPS of $20.42 (+13.5% YoY). UBS raised its price target to $1,275 and kept a Buy rating.

Original reporting
Published Aug 13, 2026, 10:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 11:02 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Are Wall Street Analysts Predicting Costco Wholesale Stock Will Climb or Sink? — source image
Decision brief

The 30-second read

$COSTNeutralLow
01

Why it matters

The text highlights slowing sales growth, fading gasoline-driven traffic, and potential margin pressure from membership saturation, rising expenses, and tariffs, while also noting bullish analyst expectations and a UBS price-target increase.

02

Market read

This is primarily an analyst-consensus and target recap with a single concrete PT change, plus qualitative risk framing around traffic and margins.

03

What to watch

The article does not quantify tariff exposure or expense pressures, so traders may be underpricing downside risk to margins versus the EPS growth narrative.

Relevance 4/10Novelty 4/10Timing: after-hours/next-session positioning around analyst target narrative

Background

Costco is described as a low-margin, high-turnover warehouse retailer with recent relative underperformance versus the S&P 500 and XLP.

Company-level read

Ticker impact

$COSTNeutralMedium confidence
Context

Article cites UBS raising Costco’s price target to $1,275 and summarizes analyst EPS growth expectations for FY ending Aug 2026.

Expected impact

Near-term price action likely tracks analyst-target revisions and sentiment around sales growth, with upside capped unless margins stabilize.

Evidence & confidence

The only concrete new catalyst in-text is the UBS price-target raise; the rest is expectation-setting (EPS growth, consensus rating) plus risk factors (membership saturation, tariffs).

Market effects

Consumer staples sentiment may remain supported if Costco’s traffic and margin concerns do not worsen.

No specific regional catalyst beyond US consumer demand framing.

Limited, as the article is focused on Costco’s US operations and analyst expectations.

Counterpoint

If membership saturation and tariff uncertainty are accelerating, the consensus “Moderate Buy” could lag reality and compress multiples despite EPS growth expectations.

Key entities

  • Costco Wholesale Corporation

    Warehouse club operator; subject of the analyst-target and outlook discussion.

  • UBS

    Raised Costco’s price target to $1,275 and maintained a Buy rating, per the article.

  • State Street Consumer Staples Select Sector SPDR ETF (XLP)

    Used as a benchmark for Costco’s relative underperformance over 52 weeks.

Related articles

$AAPLMed

Trump Tariff Refunds Just Topped $100 Billion, and These Companies Are Receiving Some of the Largest Checks

The U.S. Supreme Court invalidated Trump IEEPA tariffs, leaving the administration to refund about $166 billion. By Aug. 4, refunds exceeded $100 billion. Apple received $2.19 billion, Amazon $600 million, and others including Walmart ($2.4B), Ford ($1.3B), GM ($500M), and Costco (~$2B) are expected to receive large checks. New Section 301 tariffs may affect prices.

$PGMed

Drugmakers, retailers must face ’maximum strength’ claim in decongestant false ad litigation in US

Nasdaq sees best day in over a month as Microsoft breathes life back into AI trade By Jonathan Stempel NEW YORK, July 30 (Reuters) - A federal appeals court on Thursday revived portions of nationwide litigation in which consumers accused drugmakers such as Procter & Gamble and retailers such as CVS of selling billions of dollars of over-the-counter decongestants that didn’t work. The litigation comprised about 100 lawsuits filed after a U.S.